MegaGen Implant Designated as 'Excellent Corporate Research Institute' by Ministry of Science and ICT... "First in Industry to Receive Twice"

Megagen Implant announced on the 26th that it was designated as an ‘Excellent Corporate Research Institute for the First Half of 2024’ by the Ministry of Science and ICT and received the certificate at the designation ceremony held on the 18th of this month.

The Excellent Corporate Research Institute designation system was introduced in 2017 to discover and nurture corporate research institutes with outstanding research and development (R&D) capabilities and excellent technological innovation will and activities, aiming to drive the qualitative growth of all corporate research institutes. The designation targets corporate research institutes with excellent R&D capabilities that continuously create value through technology commercialization or have high potential. It includes research institutes that contribute significantly to corporate value and performance through systematic technology and product development from an R&D lifecycle perspective.

Since its first designation as an excellent corporate research institute in 2019, Megagen was designated once again in the first half of 2024. This achievement marks the first time in the industry that a company has been designated twice. This result came after Megagen independently verified its basic R&D capabilities and passed a rigorous three-stage evaluation by experts in each field (presentation evaluation, on-site evaluation, comprehensive evaluation). It signifies that Megagen’s outstanding R&D capabilities and continuous technological innovation have been nationally recognized, further solidifying its status as a leading company.

Megagen’s BLUEDIAMONDIMPLANT and ARi® (AnyRidge incisor) implants attracted attention. The BLUEDIAMONDIMPLANT maximizes osseointegration through a surface treatment technology that deposits calcium on the implant fixture surface for the first time in the world, under the motto of ‘an implant stronger than a strong implant.’ It provides patients with faster healing and higher success rates.

Additionally, ARi® is an implant for a new concept of anterior (front tooth) treatment. Instead of the atrophied alveolar bone, it provides strong fixation and osseointegration from the non-resorbable basal bone, enabling immediate implant placement and rapid recovery even when the alveolar bone volume is insufficient. ARi® simplifies complex surgeries that are often avoided or considered difficult in dental clinics, helping to perform accurate and efficient procedures.

Among the total of 24 companies designated as Excellent Corporate Research Institutes in the first half of 2024, Megagen was the only one designated in the Gyeongsang region, including Daegu and Gyeongbuk. With this designation, Megagen will receive various benefits for three years from the date of designation, including recommendations as a military service exemption company, preferential participation in national R&D projects, and government awards.

Hyunwook Ahn, head of Megagen’s corporate research institute, said, “With this re-designation, Megagen has further solidified its status as a leading company. Going forward, Megagen will continue to lead the industry based on its nationally recognized R&D capabilities and continuous technological innovation, and do its best to elevate the status of K-Implants in the global dentistry market.”